From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服买家考虑的状态,转变为已获批准、指定、列入清单、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的相当一部分可以在没有每次单独销售事件的情况下到来,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分销量仍将在报告结果之后出现。 在电话会议中,管理层讨论了多个产品。关键点: - Aimovig:Murdo Gordon 提到“超过 100,000 名患者开始使用 Aimovig”,并提到“我们为帮助患者尽早获得产品而设立的服务一直在解决市场上大量积压的需求”。他还提到“我们正在通过直接面向消费者的电视广告在第四季度初扩大患者教育”。这描述了强劲的上市,但并未明确说明公司已进入一个具体的买方系统(如处方集或报销路径),使得未来业务无需每次销售事件即可自动到来。虽然提到了“有利的批准率”和“患者迅速转向商业覆盖”,但这更多是常规的销售和报销关系,而非新的准入状态。 - Repatha:管理层提到“我们上周做出了一个重要决定,以改善 Repatha 的可及性和可负担性,特别是针对 Medicare Part D 患者”,并推出了新的 NDC,列表价为 5,850 美元,以降低患者的自付费用。这涉及定价和准入,但并未明确说明公司已进入一个具体的系统,使得未来业务自动流动。这更像是定价策略,而非新的准入状态。 - 生物类似药:KANJINTI 和 AMGEVITA 在欧洲上市,但管理层表示“我们很高兴在欧洲推出了我们的第一个商业生物类似药产品”,并提到“我们预计这项业务将在未来几年成为重要的增长驱动力”。这描述了上市,但并未明确说明公司已进入一个具体的采购或报销系统,使得未来业务无需每次销售事件即可自动到来。 - 其他产品:如 Prolia、KYPROLIS 等,管理层讨论了销售增长,但未提及新的准入状态。 管理层没有明确描述公司最近从需要说服买家考虑的状态转变为已获批准、指定、列入清单、合格、注册、报销或预先授权的选择,进入买家自身的系统。虽然提到了报销和准入,但更多是常规的销售和报销关系,而非新的、具体的系统准入。此外,管理层也没有明确传达这种准入状态是新的,以至于大部分销量仍将在未来。 因此,答案应为 NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.